Tiziana Life Science Ltd is a biopharmaceutical firm in the clinical stage that develops breakthrough therapies by utilizing transformational drug-delivery technologies.
The innovative nasal, oral and inhalation methods in development by the company have the potential to improve efficacy and safety as well as tolerability when compared with intravenous (IV).
In studies, Tiziana’s lead candidate intranasal folalumab (the only anti-CD3 fully human mAb) has shown a positive safety profile as well as a good clinical response.
Tiziana life Sciences Ltd announced that a poster titled “Treatment of Six Non-Active Second Progressive MS with Nasal Anti CD3 Monoclonal Antibody Foralumab: Safety, Biomarker and Disability Outcomes” will be presented during the 39th Congress of European Committee for Treatment and Research of Multiple Sclerosis, which is being held in Milan (Italy) from October 11-13 2023.
The biopharmaceutical firm said ECTRIMS was a non-profit organisation that is Europe’s and world’s largest organization of professionals dedicated to understanding and treating MS.
Tiziana pointed out that Foralumab is the only monoclonal anti-CD3 antibody (mAb) made by humans. It binds the T cell receptor, dampens the inflammation, and suppresses the effector features of multiple immune cell subsets.
This effect was also demonstrated in patients suffering from COVID, multiple sclerosis and healthy subjects.
Tiziana Health Sciences Ltd announced that it had begun site initiation of its intranasal lead foralumab clinical program, which is entering Phase 2a testing for non-active Secondary Progressive Multiple Sclerosis patients (naSPMS).
After a meeting between investigators and principal investigators from Brigham and Women’s Hospital – a founding member in the Mass General Brigham Healthcare System – the biotechnology firm announced , in a press release, that up to 10 new sites for clinical trials will be recruited.
Tiziana Life Sciences Ltd has announced that a study validating the mechanisms of action of their drug candidate, intranasal Foralumab, in Alzheimer’s Disease was published in the prestigious Proceedings of the National Academy of Sciences journal (PNAS).
The company stated that “Nasal Administration Of Anti-CD3 Monoclonal Antibody (mAb) Alleviates Disease In A Mouse Model Of Alzheimer’s Disease” is the second publication related to intranasal monoclonal anti-CD3 antibody published in PNAS in this year.
Zak’s Small Cap Research provided feedback on a “key opinion leader virtual” event hosted by Tiziana Health Sciences Ltd.
The set-piece came about after encouraging results were published from a clinical trial using Tiziana’s leading drug to treat secondary progressive multiplesclerosis (an advanced form of disease).
The treatment was continued after six months. There were no side effects and the nasally administered Foralumab by Tiziana was well tolerated.
Tiziana Health Sciences Ltd Chief Medical Officer and Chief Operating Officer Matthew Davis speaks with Thomas Warner after the company’s clinical-stage biopharmaceutical firm announced the publication of an updated study on the potential use of Foralumab Nasal Spray as a treatment of Alzheimer’s Disease.
David explains the study was published in the Proceedings of the National Academy of Science journal (PNAS). The study demonstrated significant improvements to Alzheimer’s related factors, independent of amyloid alpha and tau protein.
He emphasizes the importance of the development in context of Alzheimer’s Treatmentm by saying that current FDA-approved medications target amyloid beta protein and tau, but Foralumab uses a unique approach to reset activated microglia cells in the brain back to a baseline.
Tiziana has made significant progress in its plans to launch a study on Alzheimer’s Disease (AD) as well as a phase IIa trial with its leading product, foralumab intranasal.
